Integral Health Asset Management LLC Invests $1.27 Million in Alto Neuroscience, Inc. (NYSE:ANRO)

Integral Health Asset Management LLC purchased a new stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 300,000 shares of the company's stock, valued at approximately $1,269,000. Integral Health Asset Management LLC owned 1.11% of Alto Neuroscience at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ANRO. Wells Fargo & Company MN lifted its stake in Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock worth $46,000 after purchasing an additional 3,139 shares during the period. Deutsche Bank AG lifted its stake in Alto Neuroscience by 31.3% during the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock worth $64,000 after purchasing an additional 3,629 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new position in Alto Neuroscience during the fourth quarter worth about $74,000. Jane Street Group LLC lifted its stake in Alto Neuroscience by 72.0% during the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after purchasing an additional 7,783 shares during the period. Finally, Rhumbline Advisers increased its holdings in shares of Alto Neuroscience by 24.4% during the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock worth $108,000 after buying an additional 5,008 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have recently weighed in on ANRO. Wedbush reaffirmed a "neutral" rating and set a $4.00 price objective on shares of Alto Neuroscience in a report on Thursday. HC Wainwright began coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They set a "buy" rating and a $10.00 price objective for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a report on Friday, March 21st. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Alto Neuroscience has a consensus rating of "Moderate Buy" and an average target price of $15.40.

Alto Neuroscience Trading Up 5.0%

ANRO stock traded up $0.12 during midday trading on Friday, reaching $2.55. The company's stock had a trading volume of 217,225 shares, compared to its average volume of 384,765. Alto Neuroscience, Inc. has a 52 week low of $1.60 and a 52 week high of $17.55. The stock has a market cap of $69.06 million, a PE ratio of -1.00 and a beta of 1.87. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The business's 50-day simple moving average is $2.37 and its 200-day simple moving average is $3.43.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06. As a group, sell-side analysts expect that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.